Ver­sant-backed Bright Peak sets a date to bring its IL-2 in­to the clin­ic — but all eyes are on an IPO af­ter lat­est mega-round drops

Just un­der a year af­ter se­cur­ing its first ven­ture round, a Ver­sant-backed start­up has pulled in a mas­sive Se­ries B haul to cre­ate de­sign­er cy­tokines —and it seems as though CEO Fredrik Wik­lund is keep­ing the S-1 pa­per­work in his back pock­et.

Bright Peak Ther­a­peu­tics un­veiled a $107 mil­lion Se­ries B round on Thurs­day morn­ing, led by RA Cap­i­tal with some help from Ver­sant, Fi­deli­ty Man­age­ment & Re­search Com­pa­ny, In­vus, Qatar In­vest­ment Au­thor­i­ty, Black­Rock, Alexan­dria Ven­ture In­vest­ments and an undis­closed in­vestor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER